Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.
Identifieur interne : 000B55 ( Main/Exploration ); précédent : 000B54; suivant : 000B56Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.
Auteurs : Olivier Godeaux [Belgique] ; Patricia Izurieta [Belgique] ; Miguel Madariaga [États-Unis] ; Mamadou Dramé [États-Unis] ; Ping Li [États-Unis] ; David W. Vaughn [Belgique]Source :
- Vaccine [ 1873-2518 ] ; 2015.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques, Adolescent, Adulte, Adulte d'âge moyen, Anticorps antiviraux (immunologie), Anticorps antiviraux (sang), Facteurs temps, Femelle, Humains, Jeune adulte, Mâle, Réserve stratégique (normes), Sous-type H5N1 du virus de la grippe A (immunologie), Séroconversion, Tests d'inhibition de l'hémagglutination, Vaccination, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- effets indésirables : Vaccins antigrippaux.
- immunologie : Anticorps antiviraux, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux.
- normes : Réserve stratégique.
- sang : Anticorps antiviraux.
- Adjuvants immunologiques, Adolescent, Adulte, Adulte d'âge moyen, Facteurs temps, Femelle, Humains, Jeune adulte, Mâle, Séroconversion, Tests d'inhibition de l'hémagglutination, Vaccination.
English descriptors
- KwdEn :
- Adjuvants, Immunologic, Adolescent, Adult, Antibodies, Viral (blood), Antibodies, Viral (immunology), Female, Hemagglutination Inhibition Tests, Humans, Influenza A Virus, H5N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Male, Middle Aged, Seroconversion, Strategic Stockpile (standards), Time Factors, Vaccination, Young Adult.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , adverse effects : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , immunology : Antibodies, Viral, Influenza Vaccines.
- chemical : Adjuvants, Immunologic.
- immunology : Influenza A Virus, H5N1 Subtype.
- standards : Strategic Stockpile.
- Adolescent, Adult, Female, Hemagglutination Inhibition Tests, Humans, Male, Middle Aged, Seroconversion, Time Factors, Vaccination, Young Adult.
Abstract
Stockpiling vaccine for deployment in the event of an influenza pandemic is an important mitigation strategy. A necessary aspect of stockpiling is to determine the shelf-life of the stored vaccine.
DOI: 10.1016/j.vaccine.2014.07.062
PubMed: 25090645
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000780
- to stream PubMed, to step Curation: 000780
- to stream PubMed, to step Checkpoint: 000633
- to stream Ncbi, to step Merge: 001902
- to stream Ncbi, to step Curation: 001902
- to stream Ncbi, to step Checkpoint: 001902
- to stream Main, to step Merge: 000B59
- to stream Main, to step Curation: 000B55
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.</title><author><name sortKey="Godeaux, Olivier" sort="Godeaux, Olivier" uniqKey="Godeaux O" first="Olivier" last="Godeaux">Olivier Godeaux</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline Vaccines, Wavre, Belgium. Electronic address: olivier.o.godeaux@gsk.com.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GlaxoSmithKline Vaccines, Wavre</wicri:regionArea><wicri:noRegion>Wavre</wicri:noRegion></affiliation></author><author><name sortKey="Izurieta, Patricia" sort="Izurieta, Patricia" uniqKey="Izurieta P" first="Patricia" last="Izurieta">Patricia Izurieta</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline Vaccines, Wavre, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GlaxoSmithKline Vaccines, Wavre</wicri:regionArea><wicri:noRegion>Wavre</wicri:noRegion></affiliation></author><author><name sortKey="Madariaga, Miguel" sort="Madariaga, Miguel" uniqKey="Madariaga M" first="Miguel" last="Madariaga">Miguel Madariaga</name><affiliation wicri:level="2"><nlm:affiliation>Naples Community Hospital, Naples, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Naples Community Hospital, Naples, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Drame, Mamadou" sort="Drame, Mamadou" uniqKey="Drame M" first="Mamadou" last="Dramé">Mamadou Dramé</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline Vaccines, King of Prussia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline Vaccines, King of Prussia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Li, Ping" sort="Li, Ping" uniqKey="Li P" first="Ping" last="Li">Ping Li</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline Vaccines, King of Prussia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline Vaccines, King of Prussia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Vaughn, David W" sort="Vaughn, David W" uniqKey="Vaughn D" first="David W" last="Vaughn">David W. Vaughn</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline Vaccines, Rixensart, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GlaxoSmithKline Vaccines, Rixensart</wicri:regionArea><wicri:noRegion>Rixensart</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25090645</idno><idno type="pmid">25090645</idno><idno type="doi">10.1016/j.vaccine.2014.07.062</idno><idno type="wicri:Area/PubMed/Corpus">000780</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000780</idno><idno type="wicri:Area/PubMed/Curation">000780</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000780</idno><idno type="wicri:Area/PubMed/Checkpoint">000633</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000633</idno><idno type="wicri:Area/Ncbi/Merge">001902</idno><idno type="wicri:Area/Ncbi/Curation">001902</idno><idno type="wicri:Area/Ncbi/Checkpoint">001902</idno><idno type="wicri:Area/Main/Merge">000B59</idno><idno type="wicri:Area/Main/Curation">000B55</idno><idno type="wicri:Area/Main/Exploration">000B55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.</title><author><name sortKey="Godeaux, Olivier" sort="Godeaux, Olivier" uniqKey="Godeaux O" first="Olivier" last="Godeaux">Olivier Godeaux</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline Vaccines, Wavre, Belgium. Electronic address: olivier.o.godeaux@gsk.com.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GlaxoSmithKline Vaccines, Wavre</wicri:regionArea><wicri:noRegion>Wavre</wicri:noRegion></affiliation></author><author><name sortKey="Izurieta, Patricia" sort="Izurieta, Patricia" uniqKey="Izurieta P" first="Patricia" last="Izurieta">Patricia Izurieta</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline Vaccines, Wavre, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GlaxoSmithKline Vaccines, Wavre</wicri:regionArea><wicri:noRegion>Wavre</wicri:noRegion></affiliation></author><author><name sortKey="Madariaga, Miguel" sort="Madariaga, Miguel" uniqKey="Madariaga M" first="Miguel" last="Madariaga">Miguel Madariaga</name><affiliation wicri:level="2"><nlm:affiliation>Naples Community Hospital, Naples, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Naples Community Hospital, Naples, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Drame, Mamadou" sort="Drame, Mamadou" uniqKey="Drame M" first="Mamadou" last="Dramé">Mamadou Dramé</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline Vaccines, King of Prussia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline Vaccines, King of Prussia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Li, Ping" sort="Li, Ping" uniqKey="Li P" first="Ping" last="Li">Ping Li</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline Vaccines, King of Prussia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline Vaccines, King of Prussia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Vaughn, David W" sort="Vaughn, David W" uniqKey="Vaughn D" first="David W" last="Vaughn">David W. Vaughn</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline Vaccines, Rixensart, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>GlaxoSmithKline Vaccines, Rixensart</wicri:regionArea><wicri:noRegion>Rixensart</wicri:noRegion></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Adolescent</term><term>Adult</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (immunology)</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Influenza A Virus, H5N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (immunology)</term><term>Male</term><term>Middle Aged</term><term>Seroconversion</term><term>Strategic Stockpile (standards)</term><term>Time Factors</term><term>Vaccination</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps antiviraux (sang)</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Réserve stratégique (normes)</term><term>Sous-type H5N1 du virus de la grippe A (immunologie)</term><term>Séroconversion</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Réserve stratégique</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Strategic Stockpile</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Seroconversion</term><term>Time Factors</term><term>Vaccination</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Séroconversion</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Stockpiling vaccine for deployment in the event of an influenza pandemic is an important mitigation strategy. A necessary aspect of stockpiling is to determine the shelf-life of the stored vaccine.</div></front></TEI><affiliations><list><country><li>Belgique</li><li>États-Unis</li></country><region><li>Floride</li><li>Pennsylvanie</li></region></list><tree><country name="Belgique"><noRegion><name sortKey="Godeaux, Olivier" sort="Godeaux, Olivier" uniqKey="Godeaux O" first="Olivier" last="Godeaux">Olivier Godeaux</name></noRegion><name sortKey="Izurieta, Patricia" sort="Izurieta, Patricia" uniqKey="Izurieta P" first="Patricia" last="Izurieta">Patricia Izurieta</name><name sortKey="Vaughn, David W" sort="Vaughn, David W" uniqKey="Vaughn D" first="David W" last="Vaughn">David W. Vaughn</name></country><country name="États-Unis"><region name="Floride"><name sortKey="Madariaga, Miguel" sort="Madariaga, Miguel" uniqKey="Madariaga M" first="Miguel" last="Madariaga">Miguel Madariaga</name></region><name sortKey="Drame, Mamadou" sort="Drame, Mamadou" uniqKey="Drame M" first="Mamadou" last="Dramé">Mamadou Dramé</name><name sortKey="Li, Ping" sort="Li, Ping" uniqKey="Li P" first="Ping" last="Li">Ping Li</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25090645
|texte= Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25090645" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |